CStone Pharmaceuticals

2616 · HKEX

Public Market Listing

2616HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for CStone Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
RETSmall molecule
Non-Small Cell Lung Cancer
Sugemalimab(Cejemly)
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Sugemalimab · CejemlyPhase 3Extranodal NK/T-cell Lymphoma
Est. primary completion 2029-12 · NCT05700448 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalPralsetinibFDA updates Boxed Warning on Pralsetinib (NDA213721)
US, FDA · FDA · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$38M$43M$131M$61Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$57M$17M$92M$13Mreport ↗
2023-FY—$76M—$52Mreport ↗